These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 8165616)

  • 1. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J; Stehle G; Augustin J; Zimmermann R
    Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
    Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
    J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
    Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
    Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
    Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
    Kristensen HI; Ostergaard PB; Nordfang O; Abildgaard U; Lindahl AK
    Thromb Haemost; 1992 Sep; 68(3):310-4. PubMed ID: 1332210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
    Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of low molecular weight heparins.
    Harenberg J
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():12-8. PubMed ID: 1962899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of low molecular weight heparin by protamine chloride in vivo.
    Harenberg J; Gnasso A; de Vries JX; Zimmermann R; Augustin J
    Thromb Res; 1985 Apr; 38(1):11-20. PubMed ID: 4002198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
    Diness V; Ostergaard PB
    Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Andrassy K
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].
    Harenberg J; Giese C; Knödler A; Zimmermann R; Schettler G
    Klin Wochenschr; 1986 Nov; 64(22):1171-5. PubMed ID: 3807263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers.
    Harenberg J; Jeschek M; Acker M; Malsch R; Huhle G; Heene DL
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):49-56. PubMed ID: 8845462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
    Ariëns RA; Alberio G; Moia M; Mannucci PM
    Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.